ɫ

Skip to content

Camber expands portfolio

New launches of Plerixafor Injection, Baclofen Tablets, Fluvoxamine Maleate ER Capsules, and Olmesartan Hydrochlorothiazide Tablets.

1 min read

PISCATAWAY, N.J. —Camber Pharmaceuticals continues to expand its portfolio of treatment options with the launches of Plerixafor Injection, Baclofen Tablets, Fluvoxamine Maleate ER Capsules, and Olmesartan Hydrochlorothiazide Tablets.

Product

Brand Reference

Strength/Size

ѴdzDz®

24 mg/1.2 mL (20 mg/mL)

Lioresal®

100 ct bottles of 5, 10, & 20 mg
1,000 ct bottles of 10 & 20 mg

ܱdz®

30 ct bottles of 100 & 150 mg

Benicar® HCT

30 & 90 ct bottles of 20 mg/12.5 mg 
30 & 90 ct bottles of 40 mg/12.5  mg
30 & 90 ct bottles of 40 mg/25 mg 

 These additions reinforce Camber’s commitment to broadening access to affordable, high-quality therapies while continuing to support patients and healthcare professionals nationwide.

Latest